Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications
Status:
Completed
Trial end date:
2016-12-08
Target enrollment:
Participant gender:
Summary
People with HIV infection who are taking antiretroviral therapy (ART) could be at risk for
cardiovascular disease (CVD), which can be caused by inflammation. Methotrexate (MTX) is a
medication used to treat inflammation in people with rheumatoid arthritis. This study
evaluated the safety and effectiveness of low-dose methotrexate (LDMTX) at reducing
inflammation in HIV-infected adults.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)